Concomitant neutrophil JAK2V617F mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia

British Journal of Haematology

Volumn 131, Issue 2, 2005, Pages 166-171

  Tefferi, Ayalew ^a   Sirhan, Shireen ^a   Lasho, Terra L ^a   Schwager, Susan M ^a   Li, Chin Yang ^a   Dingli, David ^a   Wolanskyj, Alexandra P ^a   Steensma, David P ^a   Mesa, Ruben ^a   Gilliland, D G ^b  

^a MAYO CLINIC   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Diagnosis; Gene expression; Mutation; Myeloproliferative; Polycythaemia; Secondary

Indexed keywords

JANUS KINASE 2; ALLOANTIGEN; CD177 PROTEIN, HUMAN; CELL SURFACE RECEPTOR; JAK2 PROTEIN, HUMAN; MEMBRANE PROTEIN; MESSENGER RNA; ONCOPROTEIN; PROTEIN TYROSINE KINASE;

ACCURACY; ALLELE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ERYTHROCYTOSIS; FEMALE; GENE EXPRESSION; GENE MUTATION; GRANULOCYTE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NEUTROPHIL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; VOLUNTEER; ADOLESCENT; ADULT; AGED; CHI SQUARE DISTRIBUTION; ENZYMOLOGY; GENETIC MARKER; GENETICS; HOMOZYGOTE; MIDDLE AGED; POLYCYTHEMIA VERA; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION; GENETIC MARKERS; GRANULOCYTES; HOMOZYGOTE; HUMANS; ISOANTIGENS; JANUS KINASE 2; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; NEUTROPHILS; POLYCYTHEMIA VERA; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTORS, CELL SURFACE; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY;

EID: 32944477304     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05743.x     Document Type: Article

References (20)

1. Al-Shami A. Mahanna W. Naccache P.H. ( 1998) Granulocyte-macrophage colony-stimulating factor-activated signaling pathways in human neutrophils. Selective activation of Jak2, Stat3, and Stat5b. Journal of Biological Chemistry, 273, 1058 1063.
2. Baxter E.J. Scott L.M. Campbell P.J. East C. Fourouclas N. Swanton S. Vassiliou G.S. Bench A.J. Boyd E.M. Curtin N. Scott M.A. Erber W.N. Green A.R. ( 2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, 1054 1061.
3. Florensa L. Besses C. Zamora L. Bellosillo B. Espinet B. Serrano S. Woessner S. Sole F. ( 2004) Endogenous erythroid and megakaryocytic circulating progenitors, HUMARA clonality assay, and PRV-1 expression are useful tools for diagnosis of polycythemia vera and essential thrombocythemia. Blood, 103, 2427 2428.
4. Goerttler P.S. Steimle C. Marz E. Johansson P.L. Andreasson B. Griesshammer M. Gisslinger H. Heimpel H. Pahl H.L. ( 2005) The Jak2V617F mutation, PRV-1 overexpression and EEC formation define a similar cohort of MPD patients. Blood, doi: 10.1182/blood-2005-04-1515. Prepublished online 28 June 2005 Vardiman J.W. (eds) ( 2001) WHO Classification of Tumors: Tumors of the Hematopoietic and Lymphoid Tissues. IARC Press, Lyon.
5. James C. Ugo V. Le Couedic J.P. Staerk J. Delhommeau F. Lacout C. Garcon L. Raslova H. Berger R. Bennaceur-Griscelli A. Villeval J.L. Constantinescu S.N. Casadevall N. Vainchenker W. ( 2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature 434, 1144 1148 Issa J.P. ( 2005) JAK2 mutation 1849G >T is rare in acute leukemias but can be found in CMML, Philadelphia-chromosome negative CML and megakaryocytic leukemia. Blood, doi: 10.1182/blood-2005-05-1800. Prepublished online 21 July 2005 Cross N.C.P. ( 2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood, doi: 10.1182/blood-2005-03-1320. Prepublished online 26 May 2005 Pahl H.L. ( 2003) Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. Blood, 102, 3569 3574.
6. Koch C.A. Lasho T.L. Tefferi A. ( 2004) Platelet-rich plasma serotonin levels in chronic myeloproliferative disorders: evaluation of diagnostic use and comparison with the neutrophil PRV-1 assay. British Journal of Haematology, 127, 34 39.
7. Kralovics R. Buser A.S. Teo S.S. Coers J. Tichelli A. van der Maas A.P. Skoda R.C. ( 2003) Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood, 102, 1869 1871.
8. Kralovics R. Passamonti F. Buser A.S. Soon-Siong T. Tiedt R. Passweg J.R. Tichelli A. Cazzola M. Skoda R.C. ( 2005) A gain of function mutation in Jak2 is frequently found in patients with myeloproliferative disorders. New England Journal of Medicine, 352, 1779 1790.
9. Levine R.L. Wadleigh M. Cools J. Ebert B.L. Wernig G. Huntly B.J. Boggon T.J. Wlodarska I. Clark J.J. Moore S. Adelsperger J. Koo S. Lee J.C. Gabriel S. Mercher T. D'Andrea A. Frohling S. Dohner K. Marynen P. Vandenberghe P. Mesa R.A. Tefferi A. Griffin J.D. Eck M.J. Sellers W.R. Meyerson M. Golub T.R. Lee S.J. Gilliland D.G. ( 2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7, 387 397.
10. Liu E. Jelinek J. Pastore Y.D. Guan Y. Prchal J.F. Prchal J.T. ( 2003) Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood, 101, 3294 3301.
11. Ma D.D. Wei A.Q. Dowton L.A. Lau K.S. Wu Z.H. Ueda M. ( 1992) Assessment of an EIA for measuring human serum erythropoietin as compared with RIA and an in-vitro bioassay. British Journal of Haematology, 80, 431 436.
12. Moliterno A.R. Hankins W.D. Spivak J.L. ( 1998) Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. New England Journal of Medicine, 338, 572 580.
13. Mossuz P. Girodon F. Donnard M. Latger-Cannard V. Dobo I. Boiret N. Lecron J.C. Binquet C. Barro C. Hermouet S. Praloran V. ( 2004) Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica, 89, 1194 1198.
14. Passamonti F. Pietra D. Malabarba L. Rumi E. Della Porta M.G. Malcovati L. Bonfichi M. Pascutto C. Lazzarino M. Cazzola M. ( 2004) Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders. British Journal of Haematology, 126, 650 656.
15. Reid C.D. ( 1987) The significance of endogenous erythroid colonies (EEC) in haematological disorders. Blood Reviews, 1, 133 140.
16. Sirhan S. Lasho T.L. Elliott M.A. Tefferi A. ( 2005) Neutrophil polycythemia rubra vera-1 expression in classic and atypical myeloproliferative disorders and laboratory correlates. Haematologica, 90, 406 408.
17. Steensma D.P. Dewald G.W. Lasho T.L. Powell H.L. McClure R.F. Levine R.L. Gilliland D.G. Tefferi A. ( 2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both ''atypical'' myeloproliferative disorders and the myelodysplastic syndrome. Blood, 106, 1207 1209 Li C.Y. ( 2000) Immunohistochemical staining for megakaryocyte c-mpl may complement morphologic distinction between polycythemia vera and secondary erythrocytosis. Blood, 96, 771 772.
18. Tefferi A. Lasho T.L. Wolanskyj A.P. Mesa R.A. ( 2004) Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia. Blood, 103, 3547 3548.
19. Tefferi A. Lasho T.L. Gilliland D.G. Dewald G. ( 2005) Is homozygosity for JAK2 V617F in myeloproliferative disorders a time-acquired phenomenon?. New England Journal of Medicine (in press) Pahl H.L. ( 2000) Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood, 95, 2569 2576.
20. V617F mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. British Journal of Haematology (in press) Zhao Z.J. ( 2005) Identification of an acquired JAK2 mutation in polycythemia vera. Journal of Biological Chemistry, 280, 22788 22792.